H EMOCH ROMA TOSIS IS A CX)MMON
genetic d isease with a prevalence of approx imately one in 300 in the Caucasian population ( 1). The disease has an autosomal recessive inheritance pattern and results in the pathological accumulation of iron in the liver, pancreas, heart and other organs, eventually leading to cirrhosis of the liver. H epatocellular carcinoma has been reported as a complication of cirrhosis in many series of hemochromatosis patients (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In this study, the prevalence of hepatocellular carcinoma was studied in 93 hemochromatosis patients ( mean follow up 7. 7 years, range zero to 3 3).
PATIENTS AND METHODS
The d iagnosis of hemoch romatosis was suspected clinically in the proband case by an elevation in serum ferritin and transferrin saturation, and confirmed by the presence of parenchymal iron overload on percutaneous liver biopsy with determination of hepatic iron concentration. Family members, particularly siblings, were investigated with a serum fe rritin, transfe rrin saturation, human lymphocyte antigens (HLA) -A and B typing, and liver biopsy was performed in pu tati ve homo- 20) . Patients wi t h other cnnditiun~ a~-sociatcd wi t h inm ove rload, such as iron-load ing anemias, multiple transfusions and po rphyria cutanca tarda, were excluded. Patie nts with a signifi canr history nf da ily alcohol consumption were o nly mc ludcd if the d iagnosis of mm overload was confirmed in an HLA-idcntical sibling without a history ot alcohol use. l ron-loaded pat ients were treated with week ly vcnesccrions of approximnrely 500 ml blood until scrum fcrritin was approximately 50 ~tg/L, follmvcd wirh serum ferritin annually and rel remmenr if iron stores rcaccumulared as previously   TABLE 1 described (2, 19) . Patients were not routinely screened fo r hepmoccllular carc ino ma hut underwent history and physical examinations at the annual review.
T he author's hospital is a national rcfc rrnl ce ntre fo r hcmoc hromatosis, although no patients were referred with a known diagnosis of hepatoce ll ula r carcinoma. A deteriorating condition (ascitcs, jaundice, bleeding) was the most common reason fo r further investigatio ns -including abdominal paracentesis, scrum alpha-fctoprotein, abdomina l ultrasound, computed tomography (CT) scan and guiJcd liver biopsyleading to a diagnosis of hepatocellular carc inllmn. Hepacoccllular carc inoma was confirmed hy one pathologi:,t (all tumuurs haJ the characteristic 1rnhe-cular pa1 tern and hil e present within 
DNA.
The expected incidence of heraroccllular carcinoma was e~timaced from Canadian age/sex spec ific deaLh rate~ from hepa toccllular carcinoma in 10-year age intervals ( 2 l ). Observed cam were treated as a Po is~nn variable anJ the 95% confidence intervals were c.;\J. culated as previously descri bed (2 2). Mortality ratios were exrressed as the o hservcd/expected cases of carcintimn.
RESULTS
Patients were followed (ma mean ni 7.7 years (range zero to 33). O f the 93 patients (59 ma le, 34 female), there were 54 proband cases a nd 39 patient, Jiscovered through fami ly ,creenin~. There were 30 patients with c irrhns1, present at initial J1agnos1s. All pattents with hepawcellu lar carcinoma bad cirrhosis and the disease was fatal in all cases. The wmo ur occurred in five of seven patients after iron depletion by vencsection therapy. All tumours were confirmed h iscolog1cally either hypercutaneo us biorsy m at aurnpsy. T here were no tumo ur~ that were comidereJ eligible for resecrinn or transplantatio n. A characteristic tumour in an iron-loaded hemoch roma tosb patient is shown in Figure 1 . The c linical fcatun:s of pauen ts with heparoccllular cmcinoma arc shown 111 Tahle l .
The expected numbe r llf cases from hcparocellular carcino ma in an age/sex marched r orulat ion over the mean follow-up period in this study was 0.02, hut seven patients were observed. Therefore, pa tien ts with hemoc hrnmatosb haJ an observed tu expected ratilt (mortality ratio) of 350 fo r her aiucellular carcinoma. The number of ohserved cases of hepatocellu lar carcintlma was considered ro be sign1ficantli mcreased because the expected number 1if cases was llUtside the 95% confidence in tervab for the nhserved number tif deaths (7) . A summary of thi s study, n inc other follow-up ,cries anJ twn autopsy se ries of hcmochromaLOs1, patients is shown in Figures 2 a nd 3 . Patien ts reported with carcinoma from other extrahepatic sites arc shown in Figure 4 . DISCUSSION Hepatocellular carcinoma in hemochromatosis: In this re trospective study of the long te rm fo llow-up of patien ts with he mochromatosis, a di agnosis of hepatocellular carcino ma was established in seven of93 patients (7.5%); it is possible that this is an underestimate of the true prevalence of hepatocellular carcinoma since small tumo urs may have been detected in othe r h emochromarosis patients a t autopsy with metic ulo us section in g of c irrhotic livers. Because the author's centre is a referral centre fo r patients with hcmochromatosis, a refe rral bias cannot be excluded in this ret rospective study. Howeve r t he close correlation between the prevalen ce of carcinoma in auropsy studies and fo llow-up studies suggests char unlike with alco holic cirrhosis, hepatocellular carcinoma is th e direct cause of death in h e mochromatosis pat ients. The elucida tion of hcmochromarosis genetics has led to t he earlier diagn osis in fa mily members in th e precirrhotic stage of disease in more recent stud ies (7.14.23 ). Pa tients that unde rgo iron d eple ti o n therapy by venesection before the developmen t of cirrhosis have a survival comparable to the general population (2 ,7) . In the present study, less than on e-third of the patients had cirrhosis at d iagnosis a nd, therefore, the population was at a lower risk of deve loping h epatocellular carcinoma than a cohort of predominantly cirrhotic patien ts. In th e comb ined series of 859 h emoch romatosis patients in fo llow-up studies, t he prevale nce of hepacocellular carcinoma was 92 of 859 (1 0.7%) (Figure 2 ). If only cirrhotic patie nts we re considered (inc luding two autopsy series), the prevalence of hepa tocelluar carcinoma was L20 of 649 (18.5%) (Figure 3 ). Hepatocellular carcinoma in cirrhosis of any cause: Many authors have noted that the risk of h epatocc l lula r carcinoma seems to be high, particularly in cirrhosis associated wit h he mochromatosis compared with othe r types of cir- eventually prove to be a more significant risk factor than that csrablishe<l for hepatitis B (26) . The detec tion of viral ma rkers for hepatitis B and C in hemochromatosis patients with heparocel lular carcinoma raises the important quest io n of co-factors in the development of the carcinoma (27) . In fact, in the 25 h e mochromatos is patients reported by Fargion ct al ( 17 ) , 40% ha<l evidence of hepatitis C.
Recent stud ies (28) have suggested the role of a mutation in the p53 gene in hepacocellular carcino ma. The proposed mechanism of carcinogenesis in cirrhosis is that a regenerative hyperplastic response may develop into a hepatoccllular carcinoma (26) . The late development of the tumour many years after the iron has been removed in hemochromatosis or many years after an alcoholic has abstaine<l is consistent with this hypothesis. Although he mochromatosis patients have a significantly in creased risk of hepatocellula r carcinoma, it seems comparable in many other studi es of non alcoholic cirrhosis. Hepatocellular carcinoma is not a featu re of other noncirrhotic diseases associate<l with iron ove rload, suc h as thalassemia and sidcroblastic anemia, suggesting that the cirrhosis -rather than iron -is the major risk factor. Screen ing for hepatocellular carcinoma: Since hepatocellular carcinoma is a known and dreaded complication of hemoch romaros is, is the re any proven value in screening hemochromatosis patients with cirrhosis for the tumour? Sensitive assays fo r alpha-fetoprotcin and real-time ultrasonography have been st udied as screening tools in hcmochromacosis and o ther types of cirrhosis ( 10, (29) (30) (31) (32) (33) . C hayviallc et al (1 0 ) followed 77 hemochromatosis patients at three-month intervals with a lpha-fetoprotein a nd ultrasound examination , and found five patients with hepatocellular carcino ma, but no effective therapy was availab le. The experience of sc ree ning hepatiti s B patie nts has also been disappointing primari ly hecausc once discovered, resection usually is no t feasible and transpla ntation for hepatocellular carcinoma has a high incidence of recurrent carcino ma (1,33). The fact that the h epatocellular carcinoma in hemoc hromatosis docs not contain excess iron raises the possibility of assessing neoplastic or prcneoplastic lesions in the liver by using the known differential <lensitics of normal and iron-loaded tissue on dual image CT scanning and magnetic resonance imaging (34 ) . The presence of iron-free foci on liver biopsy has been described in 7.4% of he mochromatosis patients; t hese patients may have a greater risk of malignant transformation (35) , but many patients (as in the present study) develop carcinoma with normal iron stores in the li ver. Prevalen ce of extrah epatic carcin oma in hemochromatosis: Several authors (5, 6) have suggested th at hemochromatosis patients may have an increased risk of cxtrahepatic carcinoma possibly because of the direct effect of iron as a carcinogen. Bra<lbear ct al (3) conclude<l in a cohort study of 208 hemoc h romatosis patients that there was nti statistically significant increased prevalence of extrahepatic carcinoma 111 hcmochromatosis. An inc reased prevalence of extrahepatic carcinoma was suggested by Bamford et al (6) who described 10 extraheparic tumours 111 45 hcmochromatosis patients (22%) and Amman ct al (5) who described six tumours in 36 cases ( l 7(Kl). The prevalence of extrahepatic carcinoma tn hemochromacosis in che pooled series 1l patients is shown in Figure 4 . The lack of specific information about age, control populations and regional differences in the prevalence of sitespecific carci noma has limited the ability to pool the data in this group of patients. Iron as a carcinogen in the general population: Population scud1cs haw suggested that th e prevalence of carcinoma of any site inc reases in patients with increased bo<ly iron stores as assessed by scrum ferritin a nd transfcrri n saturation (36) (37) (38) . Patients with cancer of the esophagus, colon, lung anJ blad<ler have a highe r transfcrrin saturation than similar patients without cancer (36,3 7) . The hypothesis that iron enha nces cancer cell growth has been studied in experimenta l animals (39, 40) and suggests tha t iron is an essential nutrient to rapidly growing neoplastic cells. lron overload often 1~ associated with immu nosupprcssion which may predispose to the development of carcinoma. It is t hese same factors that contribute to the increased risk of infection in patients with iron overload ( 41) . C hromosomal damage has also been described in lymphocyte~ from patients with hemochromatosi~ (42) . Furthcm1ore, hepatoccllular carcinoma often occurs after venesection therapy has removed excess iron from 1 the body.
CONCLUSIONS
In su mmary, h emochromacosis has a high prevalence of hcpatoccllular carcinoma as do many other causes of cir-rhosis. The presence of cirrhosis most likely is the major risk factor, although the presence of excess iron or viral infections as co-factors in the Jeveloprnent of hepatocellular carcinoma requires further study. Extrahepatic carcinomn occurs frequently in hemochromatosis, with lung anJ colon carcinoma heing the most common cxtrahepatic sites. Early diagnosis and treatment of hcmochromarosis before the development of cirrhosis is the most effective method to prevent hcpatocellular carcinoma.
